Advertisement
Advertisement
U.S. markets open in 6 hours 33 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Soligenix, Inc. (SNGX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7802-0.0398 (-4.85%)
At close: 04:00PM EST
0.8000 +0.02 (+2.54%)
After hours: 07:58PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.8200
Open0.8300
Bid0.0000 x 900
Ask0.0000 x 2900
Day's Range0.7512 - 0.8400
52 Week Range0.7512 - 2.8000
Volume615,277
Avg. Volume1,780,918
Market Cap33.45M
Beta (5Y Monthly)1.14
PE Ratio (TTM)N/A
EPS (TTM)-0.3630
Earnings DateNov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.88
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SNGX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Soligenix, Inc.
    Analyst Report: Emergent BioSolutions IncEmergent BioSolutions makes vaccines and other products intended to protect civilian and military populations from emerging infectious diseases and chemical, biological or nuclear attacks. The company generates its revenue from product sales of its smallpox vaccine (ACAM2000), its anthrax vaccines (BioThrax and AV7909), and its Narcan nasal spray (a treatment for opioid overdoses), as well as from contract development and manufacturing services and contracts and grants. The USG is the company's primary customer, and provides it with significant product development funding. EBS shares are a component of the S&P 400 Index. The company has approximately 2,200 employees.
    Rating
    Fair Value
    Economic Moat
    3 months agoArgus Research
View more
  • PR Newswire

    Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today 100% protection of non-human primates (NHPs) against lethal Sudan ebolavirus (SUDV) challenge using a bivalent, thermostabilized vaccine formulated in a single vial, reconstituted only with water immediately prior to use. This milestone is part of an ongoing collaboration w

  • Newsfile

    Soligenix Proof of Concept Uncovers Potential Treatment Option for the World's 125 Million Psoriasis Sufferers

    New York, New York--(Newsfile Corp. - November 30, 2021) - PCG Digital -- Proof of concept in the biopharmaceutical sector is a process. Efficacy tests are performed, results are recorded from each round of clinical trials, and formulation changes are made if necessary. Each iteration moves the treatment closer to an NDA filing, with an end goal of achieving FDA approval. The goal is to gather enough data during trials to make that happen. ...

  • Zacks Small Cap Research

    SNGX: Durable Immunity for RiVax® Vaccine…

    By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update RiVax® Demonstrates Durable Immunity in Mouse Model On November 4, 2021, Soligenix, Inc. (NASDAQ:SNGX) announced the publication of preclinical studies for RiVax®, the company’s heat stable ricin toxin vaccine) that showed durable protection for at least 12 months following immunization ( Novak et al., 2021 ).

Advertisement
Advertisement